Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
Q4 2016
|
AGRX |
|
Phase 3 Results |
Other |
None |
|
Q4 2016
|
ALKS |
|
Phase 3 Results |
Other |
Fast Track |
|
Q4 2016
|
ALNY |
|
Phase 1 Results |
Other |
None |
|
H2 2016
|
AXON |
|
Phase 2 Results |
Neurology |
None |
|
Q4 2016
|
BLPH |
|
Phase 2 Results |
Cardiovascular |
None |
|
Q4 2016
|
CHRS |
|
Phase 3 Results |
Other |
None |
|
Q4 2016
|
AEZS |
|
Phase 3 Results |
Endocrine |
Orphan Drug |
|
Q4 2016
|
CTRV |
|
Phase 2 Results |
Infectious Disease |
None |
|
Q4 2016
|
DRNA |
|
Phase 1/2 Results |
Oncology |
None |
|
H2 2016
|
IMGN |
|
Phase 3 Results |
Oncology |
None |
|